RE-BVS – Piemonte Repository

Sfoglia per AUTORE
SAVA T
Collezione AOU San Luigi di Orbassano

Items : 6

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18.

2016
AOU San Luigi di Orbassano
ASL Torino 5

Santini D; Messina C; Perin A; Lodde M; Fratino L; Berruti A; Mucciarini C; Nicodemo M; Bonetti A; Alesini D; Zucali PA; Vicario G; Massari F; Lo Re G; Donini M; Bortolus R; Spizzo G; D'Angelo A; Zagonel V; Procopio G; Mattioli R; Mansueto G; Facchini G; Aieta M; Scognamiglio F; Ortega C; Di Lorenzo G; Caffo O; De Giorgi U; et alii...

Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes in Journal of Clinical Oncology

2016
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Maines F; De Giorgi U; Facchini G; Fratino L; Gasparro D; Alesini D; Basso U; Tucci M; Ortega C; Scagliarini S; Verderame F; Barni S; D'Angelo A; Vicario G; Donini M; Carrozza F; Sava T; Sirotova Z; Santini D; Caffo O;

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study in Journal of Clinical Oncology

2016
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Alesini D; Fratino L; Ortega C; Tucci M; Scagliarini S; Zagonel V; Zucali PA; Morelli F; Sartori D; Sabbatini R; D'Angelo A; Donini M; Barni S; Procopio G; Sirotova Z; Sava T; Conteduca V; Galligioni E;

Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. in Urologic oncology / Urol Oncol. 2015 Jun;33(6):265.e15-21. doi: 10.1016/j.urolonc.2015.02.016. Epub 2015 Apr 20.

2015
AOU San Luigi di Orbassano

Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; et alii...

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. in European urology / Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25.

2015
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; et alii...

Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience in Journal of Clinical Oncology

2014
AOU San Luigi di Orbassano

Caffo O; Basso U; Facchini G; Gasparro D; Alesini D; Tucci M; Ortega C; Fratino L; Campadelli E; Lo Re G; Sabbatini R; Procopio G; Zucali PA; D'Angelo A; Donini M; Massari F; Ratta R; Sava T; Messina C; De Giorgi U;